Intrinsic value of Cerecor - CERC

Previous Close

$3.92

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$3.92

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of CERC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  45
  69
  104
  150
  212
  291
  391
  513
  661
  834
  1,036
  1,267
  1,527
  1,817
  2,136
  2,485
  2,863
  3,268
  3,702
  4,162
  4,648
  5,160
  5,698
  6,260
  6,848
  7,461
  8,099
  8,763
  9,453
  10,171
Variable operating expenses, $m
  670
  1,035
  1,548
  2,246
  3,169
  4,357
  5,849
  7,680
  9,882
  12,481
  15,499
  18,949
  22,840
  27,175
  31,953
  37,169
  42,816
  48,884
  55,363
  62,245
  69,519
  77,179
  85,218
  93,633
  102,422
  111,588
  121,132
  131,063
  141,389
  152,121
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  670
  1,035
  1,548
  2,246
  3,169
  4,357
  5,849
  7,680
  9,882
  12,481
  15,499
  18,949
  22,840
  27,175
  31,953
  37,169
  42,816
  48,884
  55,363
  62,245
  69,519
  77,179
  85,218
  93,633
  102,422
  111,588
  121,132
  131,063
  141,389
  152,121
Operating income, $m
  -625
  -966
  -1,445
  -2,096
  -2,957
  -4,066
  -5,458
  -7,166
  -9,221
  -11,647
  -14,463
  -17,682
  -21,313
  -25,358
  -29,817
  -34,684
  -39,953
  -45,615
  -51,662
  -58,083
  -64,871
  -72,019
  -79,521
  -87,373
  -95,575
  -104,127
  -113,034
  -122,301
  -131,936
  -141,951
EBITDA, $m
  -625
  -966
  -1,445
  -2,096
  -2,957
  -4,066
  -5,458
  -7,166
  -9,221
  -11,647
  -14,463
  -17,682
  -21,313
  -25,358
  -29,817
  -34,684
  -39,953
  -45,615
  -51,661
  -58,083
  -64,871
  -72,018
  -79,520
  -87,372
  -95,574
  -104,126
  -113,033
  -122,300
  -131,935
  -141,950
Interest expense (income), $m
  0
  0
  0
  0
  1
  1
  2
  2
  3
  4
  6
  7
  9
  11
  13
  16
  18
  21
  25
  28
  32
  36
  40
  44
  49
  54
  59
  64
  70
  75
  81
Earnings before tax, $m
  -625
  -966
  -1,445
  -2,097
  -2,959
  -4,067
  -5,460
  -7,169
  -9,225
  -11,652
  -14,470
  -17,691
  -21,324
  -25,371
  -29,832
  -34,702
  -39,974
  -45,640
  -51,690
  -58,115
  -64,907
  -72,059
  -79,565
  -87,422
  -95,629
  -104,186
  -113,098
  -122,370
  -132,011
  -142,032
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -625
  -966
  -1,445
  -2,097
  -2,959
  -4,067
  -5,460
  -7,169
  -9,225
  -11,652
  -14,470
  -17,691
  -21,324
  -25,371
  -29,832
  -34,702
  -39,974
  -45,640
  -51,690
  -58,115
  -64,907
  -72,059
  -79,565
  -87,422
  -95,629
  -104,186
  -113,098
  -122,370
  -132,011
  -142,032

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8
  12
  18
  27
  38
  52
  69
  91
  117
  148
  184
  225
  271
  323
  380
  442
  509
  581
  658
  739
  826
  917
  1,012
  1,112
  1,217
  1,326
  1,439
  1,557
  1,680
  1,807
Adjusted assets (=assets-cash), $m
  8
  12
  18
  27
  38
  52
  69
  91
  117
  148
  184
  225
  271
  323
  380
  442
  509
  581
  658
  739
  826
  917
  1,012
  1,112
  1,217
  1,326
  1,439
  1,557
  1,680
  1,807
Revenue / Adjusted assets
  5.625
  5.750
  5.778
  5.556
  5.579
  5.596
  5.667
  5.637
  5.650
  5.635
  5.630
  5.631
  5.635
  5.625
  5.621
  5.622
  5.625
  5.625
  5.626
  5.632
  5.627
  5.627
  5.630
  5.629
  5.627
  5.627
  5.628
  5.628
  5.627
  5.629
Average production assets, $m
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  2
  2
  2
  2
  3
  3
  4
  4
  5
  5
  6
  6
  7
  7
  8
  9
  9
  10
Working capital, $m
  -2
  -2
  -4
  -5
  -8
  -10
  -14
  -18
  -24
  -30
  -37
  -46
  -55
  -65
  -77
  -89
  -103
  -118
  -133
  -150
  -167
  -186
  -205
  -225
  -247
  -269
  -292
  -315
  -340
  -366
Total debt, $m
  4
  8
  13
  21
  30
  43
  59
  79
  102
  130
  162
  199
  241
  287
  338
  394
  454
  519
  589
  662
  740
  822
  908
  998
  1,092
  1,190
  1,292
  1,398
  1,508
  1,623
Total liabilities, $m
  7
  11
  17
  24
  34
  47
  63
  82
  106
  133
  166
  203
  244
  291
  342
  397
  458
  523
  592
  665
  743
  825
  911
  1,001
  1,095
  1,193
  1,295
  1,401
  1,512
  1,626
Total equity, $m
  1
  1
  2
  3
  4
  5
  7
  9
  12
  15
  18
  23
  27
  32
  38
  44
  51
  58
  66
  74
  83
  92
  101
  111
  122
  133
  144
  156
  168
  181
Total liabilities and equity, $m
  8
  12
  19
  27
  38
  52
  70
  91
  118
  148
  184
  226
  271
  323
  380
  441
  509
  581
  658
  739
  826
  917
  1,012
  1,112
  1,217
  1,326
  1,439
  1,557
  1,680
  1,807
Debt-to-equity ratio
  4.710
  6.220
  7.140
  7.720
  8.090
  8.340
  8.510
  8.630
  8.710
  8.770
  8.810
  8.850
  8.870
  8.890
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -625
  -966
  -1,445
  -2,097
  -2,959
  -4,067
  -5,460
  -7,169
  -9,225
  -11,652
  -14,470
  -17,691
  -21,324
  -25,371
  -29,832
  -34,702
  -39,974
  -45,640
  -51,690
  -58,115
  -64,907
  -72,059
  -79,565
  -87,422
  -95,629
  -104,186
  -113,098
  -122,370
  -132,011
  -142,032
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
Funds from operations, $m
  -625
  -966
  -1,445
  -2,097
  -2,959
  -4,067
  -5,460
  -7,169
  -9,225
  -11,652
  -14,470
  -17,691
  -21,324
  -25,371
  -29,832
  -34,702
  -39,974
  -45,640
  -51,690
  -58,115
  -64,907
  -72,058
  -79,564
  -87,421
  -95,628
  -104,185
  -113,097
  -122,369
  -132,010
  -142,031
Change in working capital, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Cash from operations, $m
  -625
  -965
  -1,444
  -2,095
  -2,956
  -4,065
  -5,456
  -7,165
  -9,220
  -11,646
  -14,462
  -17,683
  -21,314
  -25,361
  -29,821
  -34,690
  -39,961
  -45,625
  -51,674
  -58,098
  -64,889
  -72,040
  -79,545
  -87,401
  -95,607
  -104,163
  -113,074
  -122,345
  -131,986
  -142,005
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Free cash flow, $m
  -625
  -965
  -1,444
  -2,095
  -2,956
  -4,065
  -5,456
  -7,165
  -9,220
  -11,646
  -14,463
  -17,683
  -21,315
  -25,361
  -29,821
  -34,690
  -39,961
  -45,626
  -51,675
  -58,099
  -64,890
  -72,041
  -79,546
  -87,402
  -95,608
  -104,165
  -113,076
  -122,347
  -131,987
  -142,007
Issuance/(repayment) of debt, $m
  2
  4
  5
  7
  10
  13
  16
  20
  24
  28
  32
  37
  42
  46
  51
  56
  60
  65
  69
  74
  78
  82
  86
  90
  94
  98
  102
  106
  110
  115
Issuance/(repurchase) of shares, $m
  626
  967
  1,446
  2,098
  2,960
  4,069
  5,462
  7,171
  9,228
  11,656
  14,473
  17,695
  21,328
  25,376
  29,838
  34,709
  39,981
  45,647
  51,698
  58,123
  64,916
  72,068
  79,574
  87,432
  95,639
  104,197
  113,109
  122,382
  132,024
  142,045
Cash from financing (excl. dividends), $m  
  628
  971
  1,451
  2,105
  2,970
  4,082
  5,478
  7,191
  9,252
  11,684
  14,505
  17,732
  21,370
  25,422
  29,889
  34,765
  40,041
  45,712
  51,767
  58,197
  64,994
  72,150
  79,660
  87,522
  95,733
  104,295
  113,211
  122,488
  132,134
  142,160
Total cash flow (excl. dividends), $m
  4
  5
  7
  10
  13
  17
  21
  26
  31
  37
  43
  49
  55
  62
  68
  74
  80
  86
  92
  98
  103
  109
  114
  120
  125
  130
  136
  141
  147
  153
Retained Cash Flow (-), $m
  -626
  -967
  -1,446
  -2,098
  -2,960
  -4,069
  -5,462
  -7,171
  -9,228
  -11,656
  -14,473
  -17,695
  -21,328
  -25,376
  -29,838
  -34,709
  -39,981
  -45,647
  -51,698
  -58,123
  -64,916
  -72,068
  -79,574
  -87,432
  -95,639
  -104,197
  -113,109
  -122,382
  -132,024
  -142,045
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  1
  2
  3
  4
  6
  9
  12
  16
  22
  28
  35
  44
  53
  64
  76
  90
  104
  120
  137
  155
  175
  195
  217
  239
  263
  288
  313
  340
  368
  397
Cash available for distribution, $m
  -623
  -961
  -1,438
  -2,088
  -2,947
  -4,052
  -5,440
  -7,145
  -9,197
  -11,619
  -14,430
  -17,646
  -21,273
  -25,315
  -29,770
  -34,634
  -39,901
  -45,561
  -51,605
  -58,025
  -64,812
  -71,959
  -79,460
  -87,312
  -95,514
  -104,067
  -112,974
  -122,241
  -131,877
  -141,892
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -597
  -880
  -1,252
  -1,719
  -2,284
  -2,941
  -3,675
  -4,466
  -5,283
  -6,091
  -6,853
  -7,530
  -8,088
  -8,499
  -8,740
  -8,801
  -8,682
  -8,390
  -7,946
  -7,373
  -6,704
  -5,971
  -5,208
  -4,447
  -3,716
  -3,036
  -2,425
  -1,891
  -1,440
  -1,068
Current shareholders' claim on cash, %
  50.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

FINANCIAL RATIOS  of  Cerecor (CERC)

Valuation Ratios
P/E Ratio -2.3
Price to Sales 37
Price to Book 0
Price to Tangible Book
Price to Cash Flow -2.5
Price to Free Cash Flow -2.5
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -114.3%
Ret/ On Assets - 3 Yr. Avg. -118.5%
Return On Total Capital -152.4%
Ret/ On T. Cap. - 3 Yr. Avg. -171.6%
Return On Equity -246.2%
Return On Equity - 3 Yr. Avg. -393.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1600%
EBITDA Margin - 3 Yr. Avg. -533.3%
Operating Margin -1600%
Oper. Margin - 3 Yr. Avg. -533.3%
Pre-Tax Margin -1600%
Pre-Tax Margin - 3 Yr. Avg. -533.3%
Net Profit Margin -1600%
Net Profit Margin - 3 Yr. Avg. -533.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CERC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CERC stock intrinsic value calculation we used $28 million for the last fiscal year's total revenue generated by Cerecor. The default revenue input number comes from 2016 income statement of Cerecor. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CERC stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CERC is calculated based on our internal credit rating of Cerecor, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cerecor.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CERC stock the variable cost ratio is equal to 1495.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CERC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Cerecor.

Corporate tax rate of 27% is the nominal tax rate for Cerecor. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CERC stock is equal to 4.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CERC are equal to 0.1%.

Life of production assets of 10 years is the average useful life of capital assets used in Cerecor operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CERC is equal to -3.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $0 million for Cerecor - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 18 million for Cerecor is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cerecor at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
LLY Eli Lilly 102.44 51.30  sell
VTGN VistaGen Thera 1.28 0.03  str.sell
ALKS Alkermes 43.79 21.11  str.sell
MRK Merck&Co 66.72 22.92  str.sell
BMY Bristol-Myers 59.42 54.20  hold
JNJ Johnson&Johnso 130.22 126.96  hold
TEVA Teva Pharmaceu 21.95 22.62  buy

COMPANY NEWS

▶ Cerecor Reports Second Quarter 2018 Financial Results   [Aug-09-18 06:30AM  GlobeNewswire]
▶ Penny Stocks to Watch for August 2018   [Jul-31-18 01:37PM  Investopedia]
▶ Cerecor Announces Expansion of Leadership Team   [Jul-16-18 06:00AM  GlobeNewswire]
▶ May Top Undervalued Stock   [May-19-18 10:02AM  Simply Wall St.]
▶ CERC: Converting into a Fully Independent Healthcare Company   [May-17-18 09:55AM  Zacks Small Cap Research]
▶ Cerecor Reports First Quarter 2018 Financial Results   [May-11-18 08:15AM  GlobeNewswire]
▶ Cerecor Appoints Simon Pedder to its Board of Directors   [Apr-09-18 08:00AM  Marketwired]
▶ Flavor Of The Month: inTEST And More   [Mar-28-18 10:02AM  Simply Wall St.]
▶ What Are The Drivers Of Cerecor Incs (NASDAQ:CERC) Risks?   [Dec-25-17 05:45PM  Simply Wall St.]
▶ Should You Buy Cerecor Inc (CERC) At This PE Ratio?   [Dec-08-17 10:33AM  Simply Wall St.]
▶ Is It The Right Time To Buy Cerecor Inc (CERC)?   [Nov-20-17 12:45PM  Simply Wall St.]
▶ Cerecor Announces Leadership Changes   [08:30AM  Marketwired]
▶ Cerecor Acquires TRx Pharmaceuticals   [08:15AM  Marketwired]
▶ Best Undervalued Stock Picks   [08:02AM  Simply Wall St.]
▶ Dilution Ahead For Cerecor Inc (CERC) Shareholders?   [Oct-05-17 05:46PM  Simply Wall St.]
▶ CERC: Encouraging Results from Proof-of-Concept Study of CERC-501 in MDD   [May-10-17 02:00PM  Zacks Small Cap Research]
▶ Cerecor Inc. Closes $5.0 Million Private Placement   [Apr-28-17 08:30AM  Marketwired]
▶ CERC: Ready to Move Ahead With Phase 2/3 Study of CERC-501 in MDD   [Mar-21-17 03:00PM  Zacks Small Cap Research]
▶ Cerecor Nicotine Withdrawal Drug Fails Study (CERC)   [Dec-06-16 04:09PM  Investopedia]
▶ Cerecor Depression Drug Fails Phase 2 Trial (CERC)   [Dec-01-16 12:45PM  Investopedia]
▶ What To Watch From The Upcoming Cerecor Inc (CERC) Release   [Oct-24-16 09:59AM  at Insider Monkey]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.